CONNECT WITH US:
Jul, 24 2019 16:00 JST
Singapore eDevelopment Ltd
Global BioLife unveils naturally modified Laetose at Harvard Global Catalyst Health Summit
SINGAPORE, Jul, 24 2019 - (ACN Newswire) - SGX-listed Singapore eDevelopment Ltd (SeD) is pleased to announce the results of clinical trials conducted on Laetose(TM), a low-glycemic, naturally modified sugar, developed by its U.S. biomedical subsidiary Global BioLife Inc.
Global BioLife's Director of Scientific Initiatives Mr Daryl L.Thompson was invited to present the new formula to health ambassadors from around the world at Harvard Medical School's Global Health Catalyst Summit, an annual event that focuses on initiatives to eliminate global health disparities.
Clinical trial results show that Laetose is a new sugar product that reduces its negative impact on the body. It is a healthier sweetener that is identical to regular sugar in taste, texture and shelf life, but a naturally modified table sugar which carries 30% fewer calories and a glycemic index score of 53 as compared to a score of 100 in glucose.
"You can think of Laetose as Sugar 2.0. It is more than a low-calorie sugar, but rather a solution to sugar itself in that it was specifically formulated to fight disease," said Mr Thompson. "We've developed a formula that uses sugar the way nature intended. Laetose tastes and performs exactly like sugar as a food ingredient but it is better accepted by the body."
Mr Thompson announced the completion of human trials on Laetose, conducted at one of the foremost laboratories in the world to measure glycemic index, with additional independent testing conducted at Charles River Laboratories showing Laetose halts stimulation of lipopolysaccharide inflammation which leads to Metabolic Endotoxemia, the root of metabolic-driven disease.
Global BioLife has partnered with Quality Candy Company LLC to form a joint venture, Sweet Sense Inc., to produce and market Laetose. Sweet Sense refined the formula at its production facility and created a scalable manufacturing process for Laetose.
"Clinical trials are complete, patents have been filed and the product is ready for full-scale production," said Mr Thompson. Sweet Sense is looking to licence Laetose and is sourcing for companies with the ability to introduce Laetose into multiple food products around the world.
Shareholders and potential investors of SeD are advised to exercise caution when dealing or trading in the securities of SeD. In particular, there is no certainty or assurance that Laetose will be licensed or come close to monetisation. Shareholders and potential investors should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about actions they should take.
About Singapore eDevelopment Ltd
Incorporated on 9 September 2009 and listed on the SGX in July 2010, Singapore eDevelopment Ltd is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) information technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities. For more information, please visit: www.SeD.com.sg or email:
About Global BioLife Inc.
Global BioLife Inc. (GBLI) is a 70%-held direct subsidiary of Global BioMedical Inc., which is a wholly-owned subsidiary of Singapore BioMedical Pte. Ltd., itself a wholly-owned subsidiary of Singapore eDevelopment Ltd, a company listed on the SGX. Remaining shares are held by Global Research and Discovery Group Scientific LLC (GRDGS) at 20% and ASX-listed Holista CollTech Limited at 10%.
GBLI strives to leverage its scientific know-how and intellectual property to provide solutions to problems that have been plaguing the biomedical field for decades. Tapping the scientific expertise of GRDGS and Holista, GBLI pledges a concerted effort in R&D, drug discovery and development for the prevention, inhibition and treatment of neurological, oncology and immuno-related diseases. GBLI is also collaborating with partners to develop second generation, DEET alternative mosquito defense technologies to protect against diseases such as Zika, Dengue, West Nile Virus and Malaria. For more information, please visit:
Source: Singapore eDevelopment Ltd
Sectors: Daily Finance, Food/Beverage, BioTech, HealthCare, Cosmetics/Spec.Chem
Copyright ©2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
SDK Receives Award for Used-Plastic Chemical Recycling Business
Feb 28, 2020 16:00 JST
SDK Announces Progress Towards the Tender Offer for Shares of Hitachi Chemical Company, Ltd. (Securities Code 4217)
Feb 28, 2020 16:00 JST
NEC's Unified Communications Platform "UNIVERGE SV Series" Reaches 500,000 Shipments
Feb 28, 2020 14:32 JST
Mitsubishi Corporation and Chubu Electric Power Consortium Named Preferred Bidder for Offshore Transmission Asset in the UK
Feb 28, 2020 07:47 JST
Mazda Production and Sales Results for January 2020
Feb 27, 2020 14:03 JST
Toyota Updates Results for January 2020
Feb 27, 2020 13:35 JST
NEC Releases "Open & Virtualized RAN" White Paper
Feb 27, 2020 12:15 JST
Hitachi and Chulalongkorn University Agree on a Cooperative Relationship for Social Innovation in Thailand
Feb 27, 2020 09:44 JST
Mitsubishi Aircraft Corporation and Mitsubishi Heavy Industries Aero Engines Celebrate First Flight of First GTF Engine Produced in Japan
Feb 27, 2020 09:32 JST
NEC Partners with Juniper Networks to Enable Telefonica Chile's IP Network Fusion Project
Feb 26, 2020 16:33 JST
Lexus' Electrification Drives Sensory Experience at Milan Design Week 2020
Feb 25, 2020 18:27 JST
4 Sharp Products Win 2020 iF Design Award
Feb 25, 2020 17:37 JST
Mitsubishi Corporation and CRISP HD Agree to Business Alliance and Acquisition of Third-Party Shares
Feb 25, 2020 15:16 JST
Double Podium for TOYOTA GAZOO Racing in Austin
Feb 25, 2020 09:41 JST
Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China
Feb 25, 2020 09:10 JST
The Closure of Automobile Production in the Philippines
Feb 22, 2020 18:00 JST
Eisai Receives the President's Award of the Japan Techno-Economics Society at the 8th Technology Management and Innovation Awards
Feb 21, 2020 17:55 JST
MHPS Receives 12 Year Maintenance Service Extension for the BLCP Power Station in Thailand
Feb 21, 2020 16:07 JST
Toyota and Toyota Industries Jointly Develop New Battery for Hybrid Electric Vehicles
Feb 20, 2020 14:27 JST
NEC and Accedian partner globally to address network performance visibility challenges and predictive analytics requirements
Feb 20, 2020 13:03 JST
More Latest Release >>
Global BioLife to Present 3F Antimicrobial Fragrance at 2020 ASM Biothreats
November 15 2019 02:00 JST
Global BioLife to present Functional Fragrance Formula at the American Society for Microbiology's Biothreats Conference as a New Method to Prevent and Treat Tuberculosis
October 29 2019 09:00 JST
Global BioLife's 3F Mosquito Repellent Formula performs well in Independent Testing
June 12 2019 14:00 JST
Global BioLife's 3F Antimicrobial Fragrance shows Efficacy against Tuberculosis
January 28 2019 12:00 JST
Singapore eDevelopment's Global BioLife to present Parkinson's Research at Neuroscience 2018
November 07 2018 19:00 JST
Singapore eDevelopment Limited Announces Corporate and Business Update
June 18 2018 19:00 JST
Singapore eDevelopment's Global BioLife develops Low Glycemic Modified Sugar
May 31 2018 18:00 JST
Singapore eDevelopment's Global BioLife confirms LB2 efficacy against Ebola
March 01 2018 14:00 JST
Singapore eDevelopment's Global BioLife confirms 100% Repellency of 3F Mosquito Fragrance
November 01 2017 18:00 JST
Singapore eDevelopment's Global BioLife develops Low-GI Modified Sugar
October 24 2017 18:00 JST
More Press release >>